MRI-guided Radiation Therapy for Cancer

CF
CP
Overseen ByChristy Palodichuk
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Jonsson Comprehensive Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new method of using radiation therapy to treat individuals with solid tumors that have metastasized. The treatment, MRI-guided Stereotactic Body Radiation Therapy, uses MRI (a detailed scan) to guide radiation precisely, potentially protecting healthy tissue and delivering treatment in just one day. Individuals with one to three tumors outside the brain and spine, who have not previously received overlapping radiation, may qualify for this trial.

As an unphased trial, this study provides patients with access to innovative treatment approaches that could potentially improve outcomes.

What prior data suggests that MRI-guided stereotactic body radiation therapy is safe for treating metastatic solid tumors?

Research has shown that MRI-guided SBRT, a type of precise radiation therapy, is safe and easy for patients to handle. Studies have found that this treatment greatly reduces side effects. For example, patients experienced fewer urinary and bowel problems compared to other radiation therapies. In one study, only 27% of patients experienced these side effects, which is quite low.

Additionally, MRI-guided SBRT is well-tolerated for treating cancer that has spread to the liver. It also lowers the risk of urinary system issues, with only a 16% chance of moderate side effects.

Overall, MRI-guided SBRT appears to be a safer option for patients, with fewer side effects than other radiation methods.12345

Why are researchers excited about this trial?

MRI-guided Stereotactic Body Radiation Therapy (SBRT) is unique because it combines precise imaging with targeted radiation delivery, allowing doctors to focus on cancer cells while minimizing damage to healthy tissues. Unlike traditional radiation therapy, which often uses CT scans for guidance, this method uses real-time MRI, providing clearer images and more accurate targeting. Researchers are excited because this approach could lead to fewer side effects and potentially better outcomes, offering a significant advancement over standard treatments like conventional radiation therapy.

What evidence suggests that MRI-guided SBRT is effective for treating metastatic solid tumors?

Research has shown that MRI-guided stereotactic body radiation therapy (SBRT), which participants in this trial will receive, offers a promising treatment for patients with metastatic cancer. Studies have found that MRI-guided SBRT provides high accuracy, protecting healthy tissue while effectively targeting tumors. Specifically, one study found that this method controlled tumors in the abdomen and pelvis in over 85% of patients after two years. MRI-guided SBRT also causes fewer side effects compared to traditional methods using CT scans. Overall, this treatment is safe, well-tolerated, and has the potential to effectively control tumors.12678

Who Is on the Research Team?

AR

Ann Raldow, MD

Principal Investigator

UCLA / Jonsson Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for adults with solid tumors that have spread to other parts of the body (metastatic cancer), except those with tumors in the brain or spinal cord. Participants must be able to undergo MRI scans and radiation therapy.

Inclusion Criteria

Total bilirubin ≤ 1.5 x upper limit of normal
Informed consent obtained
Aspartate aminotransferase (AST) ≤ three times upper limit of normal
See 10 more

Exclusion Criteria

I do not have any uncontrolled infections or serious other health problems.
Pregnant or breastfeeding
MRI contraindication
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients undergo MR-guided SBRT over one treatment fraction on study. Patients also undergo MRI and CT on study and CT or PET/CT throughout the study.

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with follow-up visits at 3, 6, 9, and 12 months.

12 months
4 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • MRI-guided Stereotactic Body Radiation Therapy

Trial Overview

The study tests a precise form of radiation called MR-guided stereotactic body radiation therapy (SBRT) for treating metastatic solid tumors, using MRI imaging to target tumors more accurately. The treatment is delivered over 1-5 days.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Treatment (MR-guided SBRT)Experimental Treatment5 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Jonsson Comprehensive Cancer Center

Lead Sponsor

Trials
373
Recruited
35,200+

Viewray Inc.

Industry Sponsor

Trials
13
Recruited
1,100+

Citations

Stereotactic Magnetic Resonance-Guided Adaptive and Non ...

Stereotactic body radiotherapy (SBRT) is an effective radiation therapy technique that heavily relies upon daily image guidance to achieve the necessary ...

MRI Vs CT Stereotactic Body Radiotherapy for Prostate ...

MRI-guided SBRT is superior to CT-guided SBRT in reducing acute genitourinary and gastrointestinal toxicity caused by localized prostate cancer.

Not just a MIRAGE: The benefit of MRI-guided radiotherapy ...

MRI-guided radiation therapy offers several theoretical advantages in the context of prostate SBRT, where high accuracy and precision are ...

Multicenter analysis of MRI-guided, stereotactic body ...

MRI-guided SBRT for abdominal and pelvic LNM achieved durable local tumor control rates of over 85% after two years and was associated with a favorable toxicity ...

Magnetic Resonance-Guided Stereotactic Body Radiation ...

This clinical trial studies the side effects and how well magnetic resonance (MR)-guided stereotactic body radiation therapy (SBRT) works in ...

Reduced Toxicity Associated With MRI-Guided Adaptive ...

MRI-guided adaptive radiation led to reduced genitourinary toxicity in prostate cancer radiotherapy.

MRI-guided adaptive stereotactic body radiotherapy for the ...

The MIRAGE phase III trial demonstrated that MRgRT significantly reduced acute grade ≥ 2 genitourinary (GU) adverse events compared with CT- ...

MRI-guided radiation therapy reduces long-term side ...

The team found that patients receiving MRI-guided SBRT experienced significantly fewer urinary and bowel side effects. Specifically, 27% of MRI-guided patients ...